The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 24, 2015

Filed:

Aug. 01, 2013
Applicant:

Astellas Pharma Inc, Chuo-ku, Tokyo, JP;

Inventors:

Wataru Hamaguchi, Tokyo, JP;

Isao Kinoyama, Tokyo, JP;

Yohei Koganemaru, Tokyo, JP;

Takehiro Miyazaki, Tokyo, JP;

Osamu Kaneko, Tokyo, JP;

Ryuichi Sekioka, Tokyo, JP;

Takuya Washio, Tokyo, JP;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/55 (2006.01); C07D 209/44 (2006.01); A61K 31/4035 (2006.01); A61K 31/472 (2006.01); A61K 31/4725 (2006.01); A61K 31/4747 (2006.01); C07D 217/06 (2006.01); C07D 217/22 (2006.01); C07D 217/24 (2006.01); C07D 221/20 (2006.01); C07D 223/16 (2006.01); C07D 401/04 (2006.01);
U.S. Cl.
CPC ...
C07D 209/44 (2013.01); A61K 31/4035 (2013.01); A61K 31/472 (2013.01); A61K 31/4725 (2013.01); A61K 31/4747 (2013.01); A61K 31/55 (2013.01); C07D 217/06 (2013.01); C07D 217/22 (2013.01); C07D 217/24 (2013.01); C07D 221/20 (2013.01); C07D 223/16 (2013.01); C07D 401/04 (2013.01);
Abstract

To provide an excellent agent for preventing or treating dementia and schizophrenia based on serotonin 5-HTreceptor regulating action, it was found that a tetrahydroisoquinoline derivative characterized by a structure in which an acylguanidino group binds to a N atom of a tetrahydroisoquinoline ring or the like, and a cyclic group binds to an unsaturated ring has a potent 5-HTreceptor regulating action and an excellent pharmacological action based on the regulating action and also discovered that the tetrahydroisoquinoline derivative is useful as an agent for treating or preventing dementia, schizophrenia, and the like, whereby the present invention has been completed.


Find Patent Forward Citations

Loading…